The N3RO trial: a randomised controlled trial of docosahexaenoic acid to reduce bronchopulmonary dysplasia in preterm infants < 29 weeks’ gestation

BACKGROUND: Bronchopulmonary dysplasia (BPD) is a major cause of mortality and long-term respiratory and neurological morbidity in very preterm infants. While survival rates of very preterm infants have increased over the past two decades there has been no decrease in the rate of BPD in surviving in...

Descripción completa

Detalles Bibliográficos
Autores principales: Collins, Carmel T., Gibson, Robert A., Makrides, Maria, McPhee, Andrew J., Sullivan, Thomas R., Davis, Peter G., Thio, Marta, Simmer, Karen, Rajadurai, Victor S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4896378/
https://www.ncbi.nlm.nih.gov/pubmed/27250120
http://dx.doi.org/10.1186/s12887-016-0611-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4896378/
https://www.ncbi.nlm.nih.gov/pubmed/27250120
http://dx.doi.org/10.1186/s12887-016-0611-0

Ejemplares similares